Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial

✍ Scribed by John J.V. McMurray; James B. Young; Mark E. Dunlap; Christopher B. Granger; James Hainer; Eric L. Michelson; Steven Earle; Bertil Olofsson; Jan Östergren; Salim Yusuf; Karl Swedberg; Marc A. Pfeffer

• Book ID: 116190532
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 384 KB
• Volume: 151
• Category: Article
• ISSN: 1097-6744
• DOI: 10.1016/j.ahj.2006.02.028